Oxford Biomedica Says Sanofi To Return Rights To Two Programmes

(Alliance News) - Oxford Biomedica PLC on Monday said French pharmaceutical firm Sanofi SA plans ...

Alliance News 8 June, 2020 | 5:12PM
Email Form

(Alliance News) - Oxford Biomedica PLC on Monday said French pharmaceutical firm Sanofi SA plans to return the rights of two gene therapy programmes.

The Oxford-based cell therapy firm said Sanofi will return the rights to the SAR422459 and SAR421869 programmes.

SAR422459, Oxford Biomedica noted, is focused on treating Stargardt disease, which occurs in an area of the retina and can cause vision loss or impairment. SAR421869 is to treat Usher's syndrome, which could lead to partial or total hearing loss.

"This follows the group's announcement in February 2019 that Sanofi had informed Oxford Biomedica that it intended to seek a new partner for these two programmes which were originally partnered by the group to Sanofi back in 2009," Oxford Biomedica said.

"The timing of return of these programmes and operational details are yet to be determined. However, when the rights to the two programmes are returned, the group will undertake its own internal evaluation to determine the potential future for these programmes and decide whether to commit further resources to them."

Shares in the company closed 4.8% higher at 811.00 pence each in London on Monday.

By Eric Cunha; ericcunha@alliancenews.com

Copyright 2020 Alliance News Limited. All Rights Reserved.

Email Form

Securities Mentioned in Article

Security Name Price Change (%) Morningstar
Oxford BioMedica PLC 865.00 GBX 1.88 -
Sanofi SA 85.21 EUR -0.19

About Author

Alliance News

Alliance News provides Morningstar with continuously updating coverage of news affecting listed companies.

Audience Confirmation

By clicking 'accept' I acknowledge that this website uses cookies and other technologies to tailor my experience and understand how I and other visitors use our site. See 'Cookie Consent' for more detail.

  • Other Morningstar Websites
© Copyright 2020 Morningstar, Inc. All rights reserved.

Terms of Use        Privacy Policy        Cookies